{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2&page=9", "query": { "intervention": "Phase 2", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 37486, "total_pages": 3749, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T10:11:33.926Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03764475", "title": "Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plaque Psoriasis" ], "interventions": [ { "name": "Roflumilast", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcutis Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 332, "start_date": "2018-12-18", "completion_date": "2020-10-08", "has_results": true, "last_update_posted_date": "2022-09-02", "last_synced_at": "2026-10-24T10:11:33.926Z", "location_count": 20, "location_summary": "Beverly Hills, California • Northridge, California • San Diego, California + 16 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03764475" }, { "nct_id": "NCT07227857", "title": "A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Epileptic Encephalopathy" ], "interventions": [ { "name": "S230815- Starting dose A", "type": "DRUG" }, { "name": "S230815- Dose B", "type": "DRUG" }, { "name": "S230815- Dose C", "type": "DRUG" }, { "name": "S230815- Dose D", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "2 Years to 12 Years" }, "enrollment_count": 20, "start_date": "2025-11-24", "completion_date": "2028-04-15", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-24T10:11:33.926Z", "location_count": 5, "location_summary": "Orange, California • Boston, Massachusetts • Rochester, New York + 2 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "New York" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07227857" }, { "nct_id": "NCT01433757", "title": "Ampicillin for DYT-1 Dystonia Motor Symptoms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "DYT-1", "Dystonia" ], "interventions": [ { "name": "Ampicillin", "type": "DRUG" }, { "name": "Sugar pill", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "7 Years to 80 Years" }, "enrollment_count": 2, "start_date": "2011-09", "completion_date": "2017-06", "has_results": false, "last_update_posted_date": "2017-07-05", "last_synced_at": "2026-10-24T10:11:33.926Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01433757" }, { "nct_id": "NCT05743881", "title": "A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Respiratory Syncytial Virus", "Human Metapneumovirus" ], "interventions": [ { "name": "mRNA-1345", "type": "BIOLOGICAL" }, { "name": "mRNA-1365", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Nimenrix", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Months", "maximum_age": "24 Months", "sex": "ALL", "summary": "5 Months to 24 Months" }, "enrollment_count": 186, "start_date": "2023-02-15", "completion_date": "2029-08-31", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-10-24T10:11:33.926Z", "location_count": 12, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Melrose Park, Illinois + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Melrose Park", "state": "Illinois" }, { "city": "Lafayette", "state": "Louisiana" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05743881" }, { "nct_id": "NCT03987919", "title": "A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1879, "start_date": "2019-07-30", "completion_date": "2021-02-15", "has_results": true, "last_update_posted_date": "2022-02-14", "last_synced_at": "2026-10-24T10:11:33.926Z", "location_count": 51, "location_summary": "Birmingham, Alabama • Sheffield, Alabama • Huntington Park, California + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sheffield", "state": "Alabama" }, { "city": "Huntington Park", "state": "California" }, { "city": "Montclair", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03987919" }, { "nct_id": "NCT05352828", "title": "Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Classical Hodgkin Lymphoma", "Hodgkin Disease Refractory", "Hodgkin Disease Recurrent" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Autologous CD30.CAR-T", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tessa Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 15, "start_date": "2022-07-25", "completion_date": "2037-12-15", "has_results": false, "last_update_posted_date": "2023-04-03", "last_synced_at": "2026-10-24T10:11:33.926Z", "location_count": 5, "location_summary": "Duarte, California • Miami, Florida • Chapel Hill, North Carolina + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05352828" }, { "nct_id": "NCT00290407", "title": "Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Lymphocytic, Chronic", "Lymphoma, Small Lymphocytic" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Beta-Glucan", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "University of Louisville", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2006-03", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2018-05-04", "last_synced_at": "2026-10-24T10:11:33.926Z", "location_count": 1, "location_summary": "Louisville, Kentucky", "locations": [ { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT00290407" }, { "nct_id": "NCT00586092", "title": "A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "bevacizumab, ABT-510", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Herbert Hurwitz", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2005-09", "completion_date": "2013-02", "has_results": false, "last_update_posted_date": "2013-04-08", "last_synced_at": "2026-10-24T10:11:33.926Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00586092" }, { "nct_id": "NCT01685892", "title": "A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphocytic Leukemia, Chronic" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2012-11-29", "completion_date": "2019-08-23", "has_results": false, "last_update_posted_date": "2020-01-10", "last_synced_at": "2026-10-24T10:11:33.926Z", "location_count": 7, "location_summary": "La Jolla, California • Denver, Colorado • New York, New York + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Springfield", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01685892" }, { "nct_id": "NCT05774756", "title": "A Trial of Setmelanotide in Acquired Hypothalamic Obesity", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypothalamic Obesity" ], "interventions": [ { "name": "Setmelanotide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rhythm Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 143, "start_date": "2023-04-26", "completion_date": "2027-04-16", "has_results": true, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-24T10:11:33.926Z", "location_count": 16, "location_summary": "Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05774756" } ] }